Search Results for: Linda Marban

Capricor seeks FDA approval of deramiocel for Duchenne based on encouraging data

Linda Marbán, Capricor

The cell therapy biotech Capricor recently released new data from their Duchenne Muscular Dystrophy (DMD) trial work. The data have generated excitement in the patient advocacy community. The stock has skyrocketed. How exciting are these new data? CEO Linda Marbán is quite upbeat and I think it’s justified. The firm is now seeking FDA approval […]

Capricor seeks FDA approval of deramiocel for Duchenne based on encouraging data Read More »

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program

Capricor

How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program Read More »

J&J Bets Up to $325 million on Capricor: Big Pharma Stem Cell Move as Predicted for 2014

Big Pharma Giant Johnson & Johnson (J & J; $JNJ) announced today a $12.5 million investment in stem cells & regenerative medicine via the small biotech Capricor ($CAPR) and the potential for the bet to go into the hundreds of millions for the heart disease program. It was only 8 days ago that I made

J&J Bets Up to $325 million on Capricor: Big Pharma Stem Cell Move as Predicted for 2014 Read More »